Mental Health Nursing

More documents

Recommendations

Info

Medication management 233 Bennett, J., Done, J. and Hunt, B. (1995) ‘Assessing the side-effects of antipsychotic drugs: a survey of CPN practice’, Journal of Psychiatric and Mental Health Nursing, 2 (3): 315–30. Bigliani, V., Mulligan, R.S. and Acton, P.D. (1998) ‘Preliminary results: D 2 /D 3 like receptor binding in temporal cortex and striatum in sertindole and olanzapine treated patients’, Journal of Nuclear Medicine, 39: 319. Bleuler, M. (1974) ‘The long-term course of schizophrenic psychoses’, Psychological Medicine, 4: 244–54. Boczkowski, J.A., Zeichner, A. and De Santo, N. (1985) ‘Neuroleptic compliance among chronic schizophrenic outpatients: an intervention outcome report’, Journal of Consulting and Clinical Psychology, 53: 666–71. Buchanan, A. (1992) ‘A two-year prospective study of treatment compliance in patients with schizophrenia’, Psychological Medicine, 22: 787–97. Chan, D.W. (1984) ‘Medication compliance in a Chinese psychiatric outpatient setting’, British Journal of Medical Psychology, 57: 81–9. Churchill, D.N. (1985) ‘Compliance: how to measure it’, Medicine of Canada, 40: 1068–70. Ciompi, L. (1980) ‘Catamnestic long-term study of the course of life and ageing in schizophrenics’, Schizophrenia Bulletin, 6: 606–18. Claghorn, J., Chapman, J.P. and Abuzzahab, F.S. (1987) ‘The risks and benefits of clozapine versus chlorpromazine’, Journal of Clinical Psychopharmacology, 7: 377–84. Cochran, S.D. and Gitlin, M.J. (1988) ‘Attitudinal correlates of lithium compliance in bipolar affective disorders’, Journal of Nervous and Mental Disorders, 176: 457–64. Cramer, J.A. and Rosenheck, R. (1998) ‘Compliance with medication regimens for mental and physical disorders’, Psychiatric Services, 49: 196–201. Creese, I., Burt, D.R. and Snyder, S.H. (1976) ‘Dopamine receptor binding predicts clinical and pharmacological potencies of antipsychotic drugs’, Science, 192: 481–3. Day, J.C., Wood, G., Dewey, M. and Bentall, R.P. (1995) ‘A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients’, British Journal of Psychiatry, 166: 650–3. Department of Health (1999) The National Service Framework for Mental Health. London: The Stationery Office. Farde, L., Nordstrom, A.L. and Nyberg, S. (1992) D 1 -, D 2 and 5-HT2-receptor occupancy in clozapine treated patients’, Journal of Clinical Psychiatry, 55 (Supplement B): 67–9. Flieschhacker, W.W., Meise, U., Günther, V. and Kurz, M. (1994) ‘Compliance with antipsychotic drug treatment: influence of side-effects’, Acta Psychiatrica Scandinavica, 382: 11–15. Gabel, W. and Piezcker, A. (1985) ‘One-year outcome of schizophrenic patients – the interaction of chronic and neuroleptic treatment’, Psychopharmacology, 18: 235–9. Gray, R. (1998a) ‘Effective dosing in the use of antipsychotics for treatment of acute schizophrenia’, Mental Health Care, 1 (9): 303–4. Gray, R. (1998b) ‘Primary care of schizophrenia: what are the roles of practice and community psychiatric nurses?’, Community Mental Health, 1 (4): 5–7. Gray, R. (1999) ‘Antipsychotics, side-effects and effective management’, Mental Health Practice, 2 (7): 14–20. Gray, R. (2000) ‘Does patient education enhance compliance with clozapine? A preliminary investigation’, Journal of Psychiatric and Mental Health Nursing, 7: 285–6. Gray, R., Wykes, T. and Parr, A.M. (2001) ‘The use of outcome measures to evaluate the efficacy and tolerability of antipsychotic medication: a comparison of Thorn graduate and CPN practice’, Journal of Psychiatric and Mental Health Nursing, 8: 191–6. Haynes, R.B. (1976) ‘A critical review of the “determinant” of patients’ compliance with therapeutic regimens’, in D.L. Sackett and R.B. Haynes, (eds), Compliance with Therapeutic Regimens. Baltimore: Johns Hopkins University Press.
234 Acute Mental Health Nursing Hayward, P., Chan, N. and Kemp, R. (1995) ‘Medication self-management: a preliminary report of an intervention to improve medication compliance’, Journal of Mental Health, 4: 511–17. Helgason, L. (1990) ‘Twenty year follow-up of first psychiatric presentation for schizophrenia: what could have been prevented?’, Acta Psychiatrica Scandinavica, 81: 231–5. Hogan, T.P., Awad, A.G. and Eastwood, R. (1983) ‘A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity’, Psychological Medicine, 13: 177–83. Kane, J.M. (1989) ‘Management strategies for the treatment of schizophrenia’, Journal of Clinical Psychiatry, 60 (Supplement 12): 13–17. Kane, J., Honigfeld, G., Singer, J. and Meltzer, H. (1988) ‘Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine’, Archives of General Psychiatry, 45: 789–96. Kapur, S. and Remington, G. (1996) ‘Serotonin–dopamine D 2 receptor occupancy with low dose haloperidol treatment: a PET study’, American Journal of Psychiatry, 153: 466–73. Kemp, R. and David, A. (1996) ‘Psychosis: insight and compliance’, Current Opinion in Psychiatry, 8 (6): 357–61. Kemp, R. and David, A. (1997) ‘Reasoning and delusions’, British Journal of Psychiatry, 170: 398–405. Kemp, R., Hayward, P., Applewhaite, G., Everitt, B., and David, A. (1996) ‘Compliance therapy in psychoatic patients. Randomised controlled trial’, British Medical Journal, 312: 345–9. Kemp, R., Hayward, P. and David, A. (1997) Compliance Therapy Manual. London: Bethlem and Maudsley NHS Trust. Kemp, R., Kirov, G., Everitt, B., Hayward, P. and David, A. (1998) ‘Randomised controlled trial of compliance therapy: 18-month follow-up’, British Journal of Psychiatry, 172: 413–19. Kisling, W. (1994) ‘Compliance, quality assurance and standards for relapse prevention in schizophrenia’, Acta Psychiatrica Scandinavica, 89 (Supplement 382): 16–24. Krawiecka, M., Goldberg, D. and Vaughn, M. (1977) ‘A standardised psychiatric assessment scale for rating chronic psychotic patients’, Acta Psychiatrica Scandinavica, 55: 299–308. Lin, H.F., Spiga, R. and Fortsch, W. (1979) ‘Insight and adherence to medication in chronic schizophrenics’, Journal of Clinical Psychiatry, 40: 430–2. Linjaerde, O., Ahlfors, U.G., Bech, P., Dencker, S.J. and Elgen, K. (1987) ‘The UKU sideeffects rating scale’, Acta Psychiatrica Scandinavica, 76 (Supplement 334): 83–94. McEvoy, J.P., Apperson, L.J. and Applebaum, P.S. (1989) ‘Insight in schizophrenia. Its relationship to acute psychopathology’, Journal of Nervous and Mental Disease, 177: 43–7. Macpherson, R., Jerrom, B. and Hughes, A. (1996) ‘A controlled study of education about drug treatment in schizophrenia’, British Journal of Psychiatry, 168: 709–17. Marder, S.R. (1999) ‘Antipsychotic drugs and relapse prevention’, Schizophrenia Research, 35 (Supplement): S87–S92. Marder, S.R., Mebane, A., Chiem, C. et al. (1983) ‘A comparison of patients who refuse and consent to neuroleptic treatment’, American Journal of Psychiatry, 140: 470–2. Matted, J.A. (1989) ‘Clozapine for refractory schizophrenia: an open study of 14 patients treated for up to two years’, Journal of Clinical Psychiatry, 50 (38I): 379–91. Meichenbaum, D. and Tusk, D.C. (1987) Facilitating Treatment Adherence: A Practitioner’s Guidebook. New York: Plenum Press.
Page 1 and 2:
EDITED BY Marc Harrison David Howar
Page 4 and 5:
Acute Mental Health Nursing From Ac
Page 6 and 7:
Contents List of contributors vii F
Page 8 and 9:
List of Contributors Ian Baguley qu
Page 10 and 11:
List of Contributors ix background
Page 12 and 13:
Foreword When I first started my ca
Page 14 and 15:
An introduction to acute mental hea
Page 16 and 17:
• Care management • Management
Page 18 and 19:
organisations providing it. Followi
Page 20 and 21:
works, and to be understanding of t
Page 22 and 23:
Introduction ONE Acute psychiatric
Page 24 and 25:
Assessment framework Acute psychiat
Page 26 and 27:
Evidence suggests that the quality
Page 28 and 29:
‘Can you tell me something about
Page 30 and 31:
negative thoughts, anxiety may sugg
Page 32 and 33:
attempting to observe behaviours th
Page 34 and 35:
These scales are often used as ‘s
Page 36 and 37:
thoughts as and when they occur. Th
Page 38 and 39:
Acute psychiatric in-patient assess
Page 40 and 41:
Acute psychiatric in-patient assess
Page 42 and 43:
Introduction TWO Measuring health a
Page 44 and 45:
Measuring health and social functio
Page 46 and 47:
Page 48 and 49:
have timely, accurate and appropria
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
easy to see why many staff have bec
Page 60 and 61:
Acknowledgements Parts of this chap
Page 62 and 63:
Page 64 and 65:
Introduction THREE Social inclusion
Page 66 and 67:
Social inclusion and acute care 53
Page 68 and 69:
Health Consortium (GPMH, 1989) desc
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
professionals, belief in the value
Page 78 and 79:
in relation to the people who are a
Page 80 and 81:
networks that we can hope to help t
Page 82 and 83:
ward, and activities that they can
Page 84 and 85:
Page 86 and 87:
• Current adjustment: physical he
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Strategies for surviving acute care
Page 94 and 95:
patients said they did not get enou
Page 96 and 97:
involvement can certainly be approa
Page 98 and 99:
to exert a measure of control or ch
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Case management: perspectives of th
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Introduction SIX Integrated care pa
Page 126 and 127:
outcomes to help identify alternati
Page 128 and 129:
services. Pre-formulation helps sec
Page 130 and 131:
nature of pathway documentation can
Page 132 and 133:
Integrated care pathways: the ‘ac
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
11. Referred for neurology opinion
Page 142 and 143:
36. 11 point assessment completed B
Page 144 and 145:
Page 146 and 147:
Stage 13 Stage 14 Integrated care p
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
evealed and analysed, and change of
Page 154 and 155:
Page 156 and 157:
SEVEN Risk assessment and managemen
Page 158 and 159:
Risk assessment and management in a
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Observation 163 of people who had c
Page 178 and 179:
towards others. For nurses, having
Page 180 and 181:
no evaluative work conducted to ass
Page 182 and 183:
Observation 169 All local trusts an
Page 184 and 185:
Table 8.1 Four levels of observatio
Page 186 and 187:
most intensive level of observation
Page 188 and 189:
Observation 175 (DoH, 1999a, 2001);
Page 190 and 191:
strongly influenced by cultural iss
Page 192 and 193:
who conducted the special observati
Page 194 and 195:
Fletcher (1999) employed an ethnogr
Page 196 and 197: Observation 183 Bowers, L. and Park
Page 198 and 199: Introduction NINE Cognitive behavio
Page 200 and 201: Cognitive behaviour therapy in in-p
Page 202 and 203: provided a great deal of hope for a
Page 204 and 205: Assessment of Need (Phelan et al.,
Page 206 and 207: 3. Changing cognitive processes. 4.
Page 208 and 209: hallucinations, which are so common
Page 210 and 211: nurse practitioner. Until very rece
Page 212 and 213: Psychosocial interventions 199 clie
Page 214 and 215: Psychosocial interventions 201 a fi
Page 216 and 217: levels of staff sickness. If workin
Page 218 and 219: Psychosocial interventions 205 for
Page 220 and 221: Problem list and assessment Psychos
Page 222 and 223: should be introduced until the pati
Page 224 and 225: Psychosocial interventions 211 rece
Page 226 and 227: Psychosocial interventions 213 Barr
Page 228 and 229: Psychosocial interventions 215 Barr
Page 230 and 231: Psychosocial interventions 217 Rix,
Page 232 and 233: emphasises the need for mental heal
Page 234 and 235: encountered with their use. Anti-ps
Page 236 and 237: can be almost exclusively attribute
Page 238 and 239: to establish a link between EPS and
Page 240 and 241: Interventions to enhance compliance
Page 242 and 243: The use of cognitive behavioural in
Page 244 and 245: • giving patients information abo
Page 248: Medication management 235 Meltzer,
Page 251 and 252: 238 Index institutionalisation, 63-
show all

Mental Health Nursing

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?